Events

Event When
Citi BioPharma Conference

September 7-8, 2022

Morgan Stanley Global Healthcare Conference

September 12-14, 2022

Bank of America Global Healthcare Conference

September 14-16, 2022

Baader Investment Conference 

September 19-23, 2022

Nine-months 2022 Financial Results reporting*

October 25, 2022

Credit Suisse Healthcare Conference 

November 7-10, 2022

Full-Year 2022 Financial Results reporting*

February 7, 2023

First Quarter 2023 Financial Results reporting*

April 25, 2023

*We will be in a silent period for 10 days ahead of the financial reporting.

Half Year 2022 Financial Results

Idorsia published its half year financial results 2022 on Tuesday
July 26, 2022.

Half Year 2022 Financial Results

Aprocitentan Phase 3 successful

In May 2022, Idorsia announces that PRECISION, our Phase 3 study of aprocitentan in patients with resistant hypertension, has met both the primary and secondary endpoints.

Aprocitentan Phase 3 successful

Full Year 2021 Financial Results

Idorsia published its full year financial results 2021 on Tuesday
February 8, 2022.

Full Year 2021 Financial Results

Daridorexant Phase 3 data published in The Lancet Neurology

In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.

Daridorexant Phase 3 data published in The Lancet Neurology

Idorsia presented at the 40th J.P. Morgan Healthcare Conference

Jean-Paul Clozel, Chief Executive Officer of Idorsia, presented at the 40th J.P. Morgan Healthcare Conference on January 12, 2022. The conference took place virtually.

Idorsia presented at the 40th J.P. Morgan Healthcare Conference

Half Year 2021 Financial Results

Idorsia published its half year financial results 2021 on Tuesday
July 27, 2021.

Half Year 2021 Financial Results

Phase 3 initiation: Selatogrel in suspected AMI

In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).

Phase 3 initiation: Selatogrel in suspected AMI

Full Year 2020 Financial Results

Idorsia published its full year financial results 2020 on Thursday February 4, 2021.

Full Year 2020 Financial Results

SLEEP 2020

On August 28, 2020, the positive results from the first pivotal Phase 3 study (evaluating 25 and 50 mg doses) of our investigational dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia, were presented by Dr Thomas Roth at SLEEP 2020.

The Associated Professional Sleep Societies (APSS) event, SLEEP 2020, is the world’s largest meeting devoted entirely to clinical sleep medicine, and sleep and circadian research.

SLEEP 2020

Half Year 2020 financial results

Idorsia published its half year financial results 2020 on Thursday July 23, 2020.

Half Year 2020 financial results

Full Year 2019 Financial Results

Idorsia published its full year financial results 2019 on Thursday February 6, 2020.

Full Year 2019 Financial Results

Half Year 2019 Financial Results

Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.

Half Year 2019 Financial Results

Full Year 2018 Financial Results

Idorsia published its full year financial results 2018 on Thursday February 7, 2019.

 

Full Year 2018 Financial Results

Phase 3 initiation: Aprocitentan for resistant hypertension management

In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

 

Phase 3 initiation: Aprocitentan for resistant hypertension management

Phase 3 Advancing: Clazosentan for cerebral vasospasm

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

 

Phase 3 Advancing: Clazosentan for cerebral vasospasm

Disclaimer

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.